MARKET

CRMD

CRMD

CORMEDIX
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.25
+0.15
+2.46%
After Hours: 6.15 -0.1 -1.60% 16:31 07/28 EDT
OPEN
6.05
PREV CLOSE
6.10
HIGH
6.38
LOW
6.03
VOLUME
206.54K
TURNOVER
--
52 WEEK HIGH
18.80
52 WEEK LOW
3.860
MARKET CAP
237.84M
P/E (TTM)
-8.2880
1D
5D
1M
3M
1Y
5Y
CorMedix Inc. to Report Second Quarter 2021 Financial Results and Provide a Corporate Update on August 12
CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it will report its financial results for ...
GlobeNewswire · 8h ago
The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Order Flow Abounds, Voyager CEO, CMO To Depart, Decision Day For Bristol-Myers Squibb, ASCO Abstracts Move Stocks
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 19)
Benzinga · 05/20 12:27
Elliott Management adds Discovery, Facebook, exits F5 Networks
Elliott Management (Paul Singer) initiated position in Discovery (DISCK), Facebook (FB), Trade Desk (TTD), E2Open (ETWO), Ryanair (RYAAY) as per its latest 13F filing.Elliott cut its stake in F5 Networks
Seekingalpha · 05/17 22:07
74 Biggest Movers From Friday
Gainers MoSys, Inc. (NASDAQ: MOSY) shares climbed 50.5% to settle at $4.35 on Friday. MoSys, last week, reported a loss for its first quarter.
Benzinga · 05/17 09:21
CorMedix slumps 20% despite a surge in Q1 revenue
Biopharmaceutical company, CorMEdix ([[CRMD]] -20.5%) losses tempo despite beating Q1 revenue consensus by $0.06M, reports revenue of $0.09M.Operating expenses surged 29% to $7.2M, compared to the same quarter last year.Company reported cash and short-term...
Seekingalpha · 05/14 19:34
Mid-Afternoon Market Update: Dow Jumps 400 Points; CorMedix Shares Slide
Toward the end of trading Friday, the Dow traded up 1.19% to 34,424.80 while the NASDAQ rose 2.41% to 13,440.75. The S&P also rose, gaining 1.62% to 4,179.15.
Benzinga · 05/14 19:09
DASH, PALI, HYRE and CRMD among midday movers
Gainers: MoSys (MOSY) +43%.HyreCar (HYRE) +41%.Vivint Smart Home (VVNT) +26%.DoorDash (DASH) +26%.Intrusion (INTZ) +26%.One Stop Systems (OSS) +24%.LifeMD (LFMD) +24%.Atea Pharmaceuticals (AVIR) +24%.Cricut (CRCT) +23%.SemiLEDs (LEDS) +20%.Losers: CorMedix...
Seekingalpha · 05/14 16:39
Mid-Day Market Update: Crude Oil Rises 2%; CorMedix Shares Drop Following Q1 Results
Midway through trading Friday, the Dow traded up 0.85% to 34,310.56 while the NASDAQ rose 1.88% to 13,371.18. The S&P also rose, gaining 1.26% to 4,164.50.
Benzinga · 05/14 16:10
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CRMD. Analyze the recent business situations of CORMEDIX through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CRMD stock price target is 20.30 with a high estimate of 29.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 94
Institutional Holdings: 11.94M
% Owned: 31.37%
Shares Outstanding: 38.05M
TypeInstitutionsShares
Increased
26
1.43M
New
16
1.00M
Decreased
21
447.96K
Sold Out
12
465.44K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.12%
Pharmaceuticals & Medical Research
+1.92%
Key Executives
Non-Executive Chairman/Independent Director
Myron Kaplan
Chief Executive Officer/Director
Khoso Baluch
Chief Financial Officer/Executive Vice President
Matthew David
Executive Vice President/General Counsel
Phoebe Mounts
Executive Vice President
John Armstrong
Executive Vice President
Elizabeth Masson Hurlburt
Other
Thomas Nusbickel
Independent Director
Paulo Costa
Independent Director
Janet Dillione
Independent Director
Gregory Duncan
Independent Director
Alan Dunton
Independent Director
Steven Lefkowitz
No Data
About CRMD
CorMedix Inc. is a commercial pharmaceutical and medical device company. The Company in-licenses, develops and commercializes prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company has in-licensed the rights to develop and commercialize its product candidate, CRMD003 (Neutrolin), which addresses market opportunities in the instances in which a central venous catheter is used, such as hemodialysis, intensive care units, oncology, and patients receiving total parenteral nutrition, intravenous (IV) hydration, and/or IV medications. Neutrolin is an anti-infective solution for the prevention of catheter-related infections and thrombosis in the central venous catheter markets, such as dialysis, critical care and oncology. Neutrolin is a broad-spectrum antimicrobial/antifungal and anticoagulant combination that is active against common microbes, including antibiotic-resistant strains, and may prevent biofilm formation.

Webull offers kinds of CorMedix Inc. stock information, including NASDAQ:CRMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRMD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CRMD stock methods without spending real money on the virtual paper trading platform.